4.5 Article

Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture

Journal

VACCINE
Volume 37, Issue 24, Pages 3214-3220

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2019.04.077

Keywords

Yellow fever virus (YFV); Downstream processing; Virus purification; Inactivated vaccine; Chromatographic techniques

Funding

  1. Faperj
  2. CNPq
  3. Capes

Ask authors/readers for more resources

Yellow fever (YF) is a high-lethality viral disease, endemic in tropical regions of South America and Africa, with a population of over 900 million people under risk. A highly effective attenuated vaccine, produced in embryonated eggs, has been used for about 80 years. However, egg-based production limits manufacturing capacity, and vaccine shortage led to the emergency use of a fractional dose (1/5) by the WHO in an outbreak in Africa in 2016 and by Brazilian authorities during an outbreak in 2018. In addition, rare but fatal adverse events of this vaccine have been reported since 2001. These two aspects make clear the need for the development of a new vaccine. In an effort to develop an inactivated YF vaccine, Bio-Manguinhos/FIOCRUZ started developing a new vaccine based on the production of the attenuated 17DD virus in serum-free conditions in Vero cells propagated in bioreactors, followed by chromatography-based purification and beta-propiolactone inactivation. Virus purification was studied in this work. Capture was performed using an anion-exchange membrane adsorber (Sartobind (R) Q), resulting in a virus recovery of 80.2 +/- 4.8% and a residual DNA level of 1.3 +/- 1.6 ng/dose, thus in accordance with the recommendations of the WHO (<10 ng/dose). However, the level of host cell proteins (HCP) was still high for a human vaccine, so a second chromatography step was developed based on a multimodal resin (Capto (TM) Core 700). This step resulted in a virus recovery of 65.7 +/- 4.8% and decreased HCP levels to 345 +/- 25 ppm. The overall virus recovery in these chromatography steps was 52.7%. SDS-PAGE of the purified sample showed a band with molecular mass of 56 kDa, thus consistent with the virus envelope protein (E) and corresponding to 96.7% of identified proteins. A Western blot stained with an antibody against the E protein showed a single band, confirming the identity of the sample. (C) 2019 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available